Table 1.
Demographic characteristics at the time of transplantation
| Variable | No-induction | rATG | Basiliximab | P value |
|---|---|---|---|---|
| Number | 19 | 24 | 17 | |
| Gender (M/F) | 9/10 | 16/8 | 9/8 | ns† |
| Recipient age (years)* | 57 [27; 70] | 54 [21; 78] | 53 [25; 65] | ns‡ |
| Donor age (years)* | 52 [16; 68] | 46 [18; 74] | 61 [21; 75] | <0.05‡a |
| HLA MM* | 3 [2; 6] | 3 [1; 5] | 3 [2; 5] | ns‡ |
| 1st/2nd and 3rd KTx (n) | 19/0 | 11/13§ | 16/1 | <0.0001† |
| PRA (%)* | 4 [0; 22] | 68 [0; 96] | 6 [2; 63] | <0.0001‡b |
| CNI (TAC/CsA) (n) | 21/4 | 28/0 | 18/0 | ns† |
| CIT (hours)* | 16.2 [11.0; 20.7] | 15.4 [7.7; 20.1] | 17.2 [7.7; 21.0] | ns‡ |
| Dialysis time (years)* | 2.0 [0.2; 5.7] | 1.9 [0.5; 6.4] | 2.0 [0.6; 4.9] | ns‡ |
| Cause of renal failure | ns† | |||
| Primary GN | 9 | 9 | 4 | |
| Hereditary diseases | 2 | 5 | 4 | |
| Diabetic or ischemic nephropathy | 6 | 2 | 7 | |
| TIN | 2 | 1 | 1 | |
| ANCA vasculitis or lupus nephritis | 0 | 4 | 0 | |
| Other causes | 0 | 3 | 1 |
ANCA Anti-neutrophil cytoplasmic antibodies, CIT cold ischemic time, CNI calcineurin inhibitor, CsA cyclosporine A, GN glomerulonephritis, HLA MM HLA mismatch, PRA historical panel-reactive antibodies, measured every 3 months before transplantation (the highest number in each patient was considered), TAC tacrolimus, TIN tubulointerstitial nephritis, TxR renal transplantation
*Median [min; max]; †Chi square test P value; ‡Kruskal-Wallis test P value
Dunn's Multiple Comparison Test: aSignificant difference between the basiliximab group and the rATG group and a bsignificant difference between rATG and the no-induction or basiliximab group
§2 patients had a 3rd transplantation